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Abstract
Background: Liver transplantation is the best treatment for end-stage liver disease. The interruption of the blood
supply to the donor liver during cold storage damages the liver, affecting how well the liver will function after
transplant. The drug Simvastatin may help to protect donor livers against this damage and improve outcomes for
transplant recipients. The aim of this study is to evaluate the benefits of treating the donor liver with Simvastatin
compared with the standard transplant procedure.
Patient and methods: We propose a prospective, double-blinded, randomized phase 2 study of 2 parallel groups
of eligible adult patients. We will compare 3-month, 6-month, and 12-month graft survival after LT, in order to
identify a significant relation between the two homogenous groups of LT patients. The two groups only differ by
the Simvastatin or placebo administration regimen while following the same procedure, with identical surgical
instruments, and medical and nursing skilled staff. To reach these goals, we determined that we needed to recruit
106 patients. This sample size achieves 90% power to detect a difference of 14.6% between the two groups survival
using a one-sided binomial test.
Discussion: This trial is designed to confirm the effectiveness of Simvastatin to protect healthy and steatotic livers
undergoing cold storage and warm reperfusion before transplantation and to evaluate if the addition of
Simvastatin translates into improved graft outcomes.
Trial registration: ISRCTN27083228.
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Background
Liver transplantation (LT) is the treatment of choice for
end-stage liver disease. Ischemia/reperfusion (I/R) injury
during the conventional cold storage and preservation of
donated livers is a key determinant of graft function
after LT. Hypoxia and reperfusion activate innate mech-
anisms of inflammation that cause injury and underline
delayed graft function. [1–3] I/R injury causes almost
10% of early organ failure and can lead to the higher in-
cidence of both acute and chronic rejection. [4, 5] Sim-
vastatin suppresses the inflammatory effect in vascular
endothelial cells, thereby protecting the liver against I/R
injury and its effects on grafts from extended-criteria do-
nors. [6–9] Statins or HMG-CoA inhibitors were primarily
designed to decrease cholesterol levels. However, they have
also shown to have beneficial cholesterol-independent ef-
fects, such as up-regulating the expression of the vasopro-
tective transcription factor Kruppel-like factor 2 (KLF2)
and consequently, its derived transcriptional programs.
Simvastatin protected healthy and steatotic rat livers under-
going cold storage and warm reperfusion before transplant-
ation. [10, 11]
While the issue of I/R injury after LT has been ad-
dressed several times and pathophysiology of this entity
has been extensively investigated in the context of
pre-clinical studies, the attempts to solve this clinical
problem have been scarce and unstandardized. This pro-
posal offers a more targeted method of stratifying the
differences on the liver sinusoidal milieu. The differences
will be obtained with neither a complex therapeutic ap-
proach of combining different pharmacologic strategies
nor the usage of machine perfusion methods, but by the
sole cost of a single drug/placebo administration. In this
novel approach, the infusion of Simvastatin will be ap-
plied directly into the donor liver’s portal vein after
donor hepatectomy. The clinical trial allows avoidance
of systemic infusion, so the protocol could also be ap-
plied in cases of multiorgan deceased donor retrievals.
Donor shortage
LT is the only life-saving therapy for most types of
end-stage liver disease. In Italy, the overall rate of ca-
daver donation is 22.2 donors per million per year, and
in some regions, like Sicily, the rate is 12.6 donors per
million per year. In the past few years, IRCCS-ISMETT,
a transplant hospital in Sicily, has been committed to
counteracting this organ shortage. Over the years, the
number of transplants has steadily increased thanks to
marginal donors, living donors, and split LT. ISMETT
has implemented techniques and strategies to most effi-
ciently use valuable resources in order to maintain a
high level of LT. From July 1999 till May 2014, we per-
formed 902 LTs for adults: 755 (84%) were performed by
using 601 whole livers (80%), 99 (13%) were living-related
LTs, and 55 (7%) were split LTs. The one-year survival rate
(cadaveric liver transplantation) is 85.4%. [12–14]
The shortage of organs led to the use of steatotic liver
grafts from extended-criteria deceased brain donors
(DBDs), even though these livers are more susceptible to
I/R injury and have poorer outcomes than non-steatotic
livers. Preclinical studies have demonstrated that the
negative effects of I/R can be prevented by adding Sim-
vastatin to the cold preservation solution shortly before
procurement to protect both parenchymal and endothe-
lial components of the liver after warm reperfusion.
The proposed project aims to be the first prospective
randomized clinical trial to prove the efficacy of Simva-
statin in preventing I/R injury and expand the donor pool.
Purpose
The primary endpoint is to investigate the effect of
intra-gastric Simvastatin administration using a nasogas-
tric cannula in addition to cold-storage on 3-month,
6-month and 12-month graft survival after LT. As sec-
ondary endpoints, we will compare 3-month, 6-month
and 12-month patient survival, hospitalization stays, and
all transplant-related complications in terms of the
multi-tier Clavien grading system after LT. This will
allow us to identify a significant relation into two
homogenous groups of liver transplanted patients, only
differing for Simvastatin or non-administration regimen;
using the same procedure, with identical surgical instru-
ments, and medical and nursing skilled staff.
Methods
Trial design
The trial will employ a randomized administration of a
single oral dose of 80 mg of Simvastatin (Sandoz®, Holz-
kirchen, Germany) (Group 1) or placebo (Group 2) per
adult cadaveric donor through a nasogastric tube 1 h be-
fore the organ procurement, to investigate the effect of
these interventions on graft survival after LT.
Setting
The trial will be conducted in the operating rooms of a
private hospital in Palermo (ISMETT), Italy and in every
external hospital where all of the eligible DBDs are lo-
cated. ISMETT was developed specifically for transplant-
ation through a partnership of the Sicilian regional
government and the University of Pittsburgh Medical
Center. It is the first hospital in Southern Italy certified
by Joint Commission International for excellence in clin-
ical practice and is one of the first hospitals in Italy to
use an entirely computerized process. It includes labora-
tories for clinical chemistry, microbiology, immunology
and pathology, as well as laboratories that are equipped
to support research activities. Liver transplantation is at
the core of ISMETT transplantation programs. The
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ISMETT Abdominal Surgery and Transplantation oper-
ational unit has a team of 6 expert attending physicians
and 2 surgery fellows, who manages the selection and
care of patients requiring LT both from cadaveric and
living donor. In ISMETT there is close collaboration and
daily interdisciplinary teamwork with colleagues from
other disciplines at ISMETT, including hepatologists,
critical care clinicians, radiologists, endoscopists, and re-
searchers from Ri.MED Foundation. An intense daily
collaboration is performed with nurses, physical and re-
spiratory therapists. One skilled research nurse will be
recruited for guaranteeing the correct schedule of out-
patient visit examinations, patient appointments and
maximize the adherence. Ri.MED investigator will co-
ordinate the effective functioning of the data and safety
monitoring board (DSMB), maintaining information
reviewed, discussed and recorded with the strict confi-
dentiality. In addition, she will ensure the correct data
recording of retrieval procedures, patient enrolment and
data analysis in agreement DSMB recommendations and
respect of the entire study phases.
Eligibility criteria
Participants will be deemed eligible for the trial if they
are 1) patients (male and female) over 18 years of age, 2)
deceased brain donors (male and female) over 18 years
of age, 3) female patients who are of child-bearing po-
tential must ensure effective methods of birth control
during the first 6 months of study following the whole
LT, 4) patients with end-stage liver disease or terminal
cancer liver disease, and a suitable candidate are placed
on waiting list for primary LT at IRCCS-ISMETT, 5) pa-
tients who underwent liver transplantation from de-
ceased brain donors (not identical human leukocyte
antigen - HLA) compatible in terms of blood group
ABO, 6) patients who can understand the purpose and
risks of the study, have been fully informed and given
written informed consent, 7) patients who are unable to
read and/or write, but are fully capable of understanding
the oral proposal by the researcher (or the appointed rep-
resentative) and have given oral informed consent that is
testified in writing by an independent third person.
The following subjects will be excluded by donor popula-
tion: 1) pregnant or breast-feeding donors, 2) donor with
autoimmune disease or allergies to statins, 3) donors re-
quiring ongoing dosing with a systemic immunosuppressive
drug at time of harvesting procedures, 4) donors known to
be human immunodeficiency virus (HIV) positive, 5) do-
nors with malignancy or history of malignancy, except for
non-metastatic basal or squamous cell carcinoma of the
skin that has been treated successfully, 6) donors had previ-
ously received or is receiving an organ transplant.
The following subjects will be excluded by recipient popu-
lation: 1) recipients with acute liver disease, 2) pediatric
patients or pediatric donors, 3) patients undergoing liver
re-transplantation, 4) patients undergoing split or living
donor liver transplantation, 5) patients undergoing com-
bined liver- or other solid (abdominal or thoracic) organ(s)
transplantation, 6) patient who is participating or have been
participated to another clinical trial/study and/or has
consumed an experimental drug in the last 30 days, 7) any
clinically relevant conditions that might affect study partici-
pation and/or study results, 8) patients with history of al-
lergy or intolerance to statins, 9) patients with history of
substance abuse, and/or psychiatric disorders or conditions
that may invalidate communication due to their inability to
understand the potential risks and benefits of the study, 10)
patients greater than 65 years old.
Interventions
Participants will be allocated to one of two groups (see
Fig. 1): Group one will receive an organ procured in a
DBD after preoperative administration of Simvastatin;
group two will comprise the control group receiving no
DBD intervention before the standard organ procure-
ment in a DBD or after.
Experimental treatment
Simvastatin tablets on the market will be pulverized and
placed in capsules in order to then be emptied at the time
of preparation of the suspension at the clinical site during
the start of the cold phase of the collection. An Investiga-
tional Medicinal Product Dossier (IMPD) will be drawn
up before the trial begins and the authorization of the Na-
tional Competent Authority (NCA) has been granted. The
drug will be administered in the deceased donor prior to
the allograft procurement by using a nasogastric tube, and
it will be subsequently transplanted into the recipient.
Two Simvastatin 40mg tablets (Sandoz®, Holzkirchen,
Germany) will be pulverized and encapsulated in order to
be emptied at the moment of the preparation into a
hydro-alcoholic suspension at the clinical site during the
start of the cold phase collection. The suspension will then
be administered via an intragastric route using a nasogas-
tric cannula one hour before vascular clamping in the
DBD surgical liver procurement procedures. [15]
Criteria for discontinuing or modifying allocated in-
terventions for a given trial participant will be defined
after histologic examinations of back-table and post-
reperfusion liver biopsies (Fig. 1). The therapeutic
intervention will be applied to the DBD before trans-
plantation, and for this reason, no strategies to im-
prove adherence to intervention protocols, and any
procedures for monitoring adherence will be imple-
mented. No relevant concomitant care and interven-
tions are prohibited during the trial.
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Usual care
Patients in group two will receive ‘usual care’ only. Pla-
cebo will include the aforementioned preoperative ad-
ministration of 2 hard jelly capsules (dimension = 0),
containing an orange-swedish microcrystalline cellulose.
Outcomes
The primary outcome measure in this trial is postopera-
tive graft survival after LT. The secondary outcomes of
interest are patient survival, hospitalization stays, and all
transplant-related complications in terms of the multi-tier
Clavien grading system after LT. The grading system is
used in order to identify a significant relation into two
homogenous groups of liver transplanted patients, which
only differ for Simvastatin or non-administration regimen
utilizing the same procedure, with identical surgical in-
struments, and medical and nursing skilled staff. Baseline
data on graft function and patient performance status will
be collected immediately prior to discharge from the re-
covery unit (T0). Follow-up measures will be collected at
three time points: 3-month (T1), 6-month (T2) and
12-month (T3), after LT (see Fig. 1). All participants will
be routinely evaluated with a post-reperfusion liver biopsy
(sample), intensive care monitoring, daily laboratory and
ultrasound examinations for the first week after the oper-
ation and when required during their hospital stay.
Sample size
We hypothesize that Simvastatin’s protective effects may
occur in the liver during the harvesting procedure from
the deceased donor and could significantly ameliorate
post-LT outcomes. To reach the above-mentioned goals,
we decided to recruit 106 patients. This sample size
achieves 90% power to detect a difference of 14.6% be-
tween the two groups survival using a one-sided bino-
mial test. The target significance level is 0.05. These
Fig. 1 Study flow diagram
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results assume a null hypothesis that the proportion of
the group with the standard procedure is 0.85.
Interim analysis
Two interim analyses of drug tolerance and efficacy will
be performed 6months after the trial enrollment start-
ing, and when 75% of participants have been enrolled in
the trial, respectively. The level of significance will main-
tain an overall P value of 0.05 and be calculated accord-
ing to the O’Brien-Fleming stopping boundaries. [16]
The DSMB will be instituted as an independent group
of experts that will advise the clinicians and the study in-
vestigators, without direct involvement in the conduct of
the study, nor financial, proprietary, professional, or
other interests that may affect impartial, independent
decision-making. The ISMETT Director of the Depart-
ment for the Treatment and Study of Abdominal
Diseases and Abdominal, the ISMETT Medical and Sci-
entific Director and the primary investigator (PI) will
have primary responsibility for the DSMB formation and
for identifying the DSMB Chair and the terms of mem-
bership for the entire duration of the study. The DSMB
will deliberate processes, including event triggers that
would call for an unscheduled review, stopping guide-
lines, unmasking (unblinding) and voting procedures
prior to initiating any data review. ISMETT investigators
will collect, assess, report, and manage solicited and
spontaneously reported adverse events and other unin-
tended effects of trial interventions or trial conduct.
Randomization
A statistician group, with no clinical involvement in the
trial, will computer-generate a stratified block random-
ized sequence, based on D-MELD score [17–19]. This
list will remain concealed from the trial coordinator at
all times. When a DBD becomes available, the trial co-
ordinator will assess the previously enrolled participant,
which was considered suitable for the above-mentioned
DBD [19]. S/he will obtain the treatment allocation by a
specific website, dedicated for electronic clinical report
form depository (https://simvalt.fullcro.org/). S/he will
then inform the appropriate donor nursing and medical
staff who will deliver the intervention(s). The trial coord-
inator will not collect outcome data, deliver the inter-
vention(s), or provide patient care.
Blinding
Outcome measures will be collected by recovery unit
medical and nursing staff that are blinded to the partici-
pants’ treatment allocation. The interventions will be de-
livered by separate groups of operative staff (operative
donor team), and each group will be blinded to the
treatment delivered by the other. The trial will adhere to
procedures to maintain separation between the data
management staff who will record the outcome data and
the donor operative nursing and medical staff who will
deliver the intervention(s).
Data collection
The data from patients enrolled in the Simvalt study are
collected by EDC (electronic data capture) using a
web-based eCRF. The link to access to eCRF is https://
simvalt.fullcro.org, the data, once entered in eCRF, are
stored in a database. The credentials (user name and
password) to access to eCRF are given individually to
each user upon request of the Sponsor, after the request
the credentials are provided within 1 working day; the
password respects the security requirements (it must
have at least one capital letter, one number, one special
character and it must be composed of at least ten digits).
The patient data are anonymized; it means that each pa-
tient is identified with a code which is automatically
generated by the eCRF at the moment of enrolment, in
the eCRF only the year of birth and the gender of patient
is collected, no other personal data (name, initials,
complete date of birth) are collected, so only the Investi-
gator at the site can know the identity of the patient.
Collection of laboratory evaluations, and storage of
biological specimens (liver biopsies) for genetic or mo-
lecular analysis in the current trial and for future use in
ancillary studies, will be stored at ISMETT.
Statistical analysis
Intention-to-treat analysis will be applied. Quantitative
variables will be compared with the Student t-test or the
Wilcoxon rank-sum test and categorical variables will be
compared with the chi-squared test or Fisher’s exact test
as appropriate. No a-priori criteria will be set for an
early end of the study. Data will be analyzed according
to the 2 × 2 randomized factorial study design. All of the
phases will follow the Consolidated Standards of Report-
ing Trials 2010 Statement to improve the reporting of
parallel-group randomized controlled trial, enabling
readers to understand the trial’s design, conduct, ana-
lysis. and interpretation as well as to assess the validity
of its results. It will be achieved through complete trans-
parency from study investigators. All analyses and
graphics were performed in the R statistical computing
environment, version 3.4.3.
Monitoring
Circumstances under which unblinding is permissible
are related to severe and not expectable adverse recipi-
ent reaction to Simvastatin or Placebo, and PI will be in-
volved procedure for revealing a participant’s allocated
intervention during the trial. Outcome measures will be
collected by recovery unit medical and nursing staff that
are blinded to the participants’ treatment allocation. The
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interventions will be delivered by separate groups of op-
erative staff (operative donor team), and each group will
be blinded to the treatment delivered by the other. The
trial will adhere to procedures to maintain separation
between the data management staff who will record the
outcome data and the donor operative nursing and med-
ical staff who will deliver the intervention(s). In addition,
DSMB will review the following items: 1) interim/cumu-
lative data for evidence of study-related adverse events;
2) data quality, completeness, and timeliness; 3) ad-
equacy of compliance with goals for recruitment and re-
tention; 4) adherence to the protocol; 5) factors that
might affect the study outcome or compromise the con-
fidentiality of the trial data.
DSMB will provide official communications that will
occur between EC and IRB, including: 1) modifications of
the study protocol based upon the review of the safety data;
2) suspension or early termination of the study because of
serious concerns about subjects¿ safety, inadequate per-
formance or rate of enrolment or because study objectives
have not been obtained according to pre-established statis-
tical guidelines; 3) optional approaches for clinicians and
study investigators to consider when the DSMB determines
that the incidence of primary study outcomes is substan-
tially less than expected.
Ethical considerations
The project has been approved by the hospital’s human re-
search ethics committee. Informed consent will be obtained
from all participants. ISMETT PI and co-investigators will
obtain informed consent or assent from potential trial par-
ticipants or authorized surrogates, during outpatient clinic
visits in waiting-list time and during the ISMETTadmission
date for liver transplantation.
Discussion
This trial is the first to rigorously evaluate the effect of pre-
operative DBD treatment with the administration of Simva-
statin on LT outcomes. The use of Simvastatin could reduce
donor liver damage and decrease the length of hospital stay
and the rate of complications. There is a remote probability
of liver damage with the use of statins. However, Simvastatin
is a well-known drug with a minimal reported risk of liver
damage compared with the other statins. The factorial de-
sign of the trial enables a head-to-head comparison of the
individual and cumulative effects of this intervention, which
should provide valuable evidence to inform clinical practice.
Trial status
The proposed trial has been validated and accepted for fi-
nancial support by the Italian National Health Ministry
(Programme of “Ricerca Finalizzata 2013” - Clinical health
care research - GR-2013-02357764). Patient inclusions
have been ongoing since 30 June 2018.
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